BCL11A and sickle cell disease: Fusionof the nanobody to a cell-permeant miniature protein and an E3 adaptorcreates a degrader that depletes cellular BCL11A in differentiatedprimary erythroid precursor cells, thereby inducing the expressionof fetal hemoglobin, a modifier of clinical severity of sickle celldisease and β-thalassemia.